The MDA's annual conference highlighted recent breakthroughs and the outlook for future care in the neuromuscular disease community.

The evidence for Elevidys is growing, and Sarepta is working to make the DMD treatment widely available, the company's ...

Dyne Therapeutics is advancing z-rostudirsen toward approval for DMD after data showed increased dystrophin and early functional trends.

Columnist Betty Vertin says her three sons with DMD may not have a big social life, but they have a big family that makes up for it.

Columnist Shalom Lim is using his lived experience with Duchenne muscular dystrophy to consult with organizations about ...

Dyne Therapeutics' Z-basivarsen led to gains in motor function and cognition for myotonic dystrophy type 1, and is entering a ...

In 2018, when Nell Choi was 9 years old, she began experiencing symptoms that led to hospitalization and a diagnosis of neuromyelitis optica spectrum disorder (NMOSD), type positive. A month later, ...

Share this page with email Share this page on Facebook Share this page on X Share this page on Reddit Print Preferred Source on Google The latest Phase 3 trial results continue showing that deramiocel ...

Columnist Robin Stemple knows that his physical challenges aren't his fault, but that doesn't make it any easier to avoid ...

New presentations at MDA 2026 expand the understanding of how Duvyzat may help people with Duchenne muscular dystrophy.